Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel

Masahiro Wada, Hiromitsu Jinno, Masakazu Ueda, Tadashi Ikeda, Masaki Kitajima, Tomohiro Konno, Junji Watanabe, Kazuhiko Ishihara

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)

Abstract

Background: Paclitaxel (PTX) is administered as a solution in polyoxyethylated castor oil (CO) due to its low water solubility, but solvent-induced side-effects may be severe. Materials and Methods: PMB30W is a co-polymer of 2-methacryloyloxyethyl phosphorylcholine (MPC) and butyl methacrylate (BMA). Cytotoxicities of PTX in PMB30W (PTX-PMB30W) were examined in cell culture and in vivo. Results: PTX-PMB30W and PTX in dimethyl sulfoxide showed similar toxicity in breast cancer cell lines MCF-7, SK-BR-3 and MX-1. Antitumor efficacies of PTX-PMB30W and PTX in CO (PTX-CO) were similar following weekly intraperitoneal administration of 50 mg/kg PTX in nude mice transplanted with MX-1 cells. At 200 mg/kg PTX, all animals died within 1 minute of PTX-CO administration. However, all animals receiving PTX-PBM30W survived. Ulceration occurred following subcutaneous injection of PTX-CO, but injection of PTX-PMB30W did not cause skin changes. Conclusion: Our data suggest that PMB30W can act as an effective PTX nanotransporter.

Original languageEnglish
Pages (from-to)1431-1435
Number of pages5
JournalAnticancer Research
Volume27
Issue number3 B
Publication statusPublished - 2007 May

Keywords

  • 2-methacryloyloxyethyl phosphorylcholine (MPC)
  • Co-polymer
  • Paclitaxel (PTX)
  • Tumour

Fingerprint

Dive into the research topics of 'Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel'. Together they form a unique fingerprint.

Cite this